Sclerosis News and Research

RSS

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

6 Oct 2009

Multiple Sclerosis Association of America receives National Health Information Awards

The Multiple Sclerosis Association of America (MSAA) received four communications awards, which included two APEX Awards and two National Health Information Awards.

5 Oct 2009

Myocardial and neurological effects of Tβ4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on the results of several important research programs with Thymosin beta 4 (Tβ4) presented at the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

5 Oct 2009

National experts to address epilepsy disorder

The Epilepsy Foundation of Minnesota is partnering with Mayo Clinic to host a regional patient education conference called “Living with Seizures: Today & Tomorrow.” The regional conference will feature national experts in epilepsy, panel discussions and breakout sessions that include the following topics:

5 Oct 2009

AMERIGROUP Foundation and ALS Association support the Grommet Island park project

The AMERIGROUP Foundation teamed up with the ALS Association today in support of a 4K walk, groundbreaking and beach party to benefit the Grommet Island park project - a first of its kind, 100 percent handicap-accessible oceanfront destination - in Virginia Beach.

4 Oct 2009

Retinoic acid may provide relief for ulcerative colitis

Here's another reason why you should take your vitamins. A new research report appearing in the October 2009 print issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that retinoic acid, the oxidized form of vitamin A, could be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases.

3 Oct 2009

Nutra Pharma manufactures first commercial batch of Cobroxin

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has completed manufacturing the first commercial batch of Cobroxin and has successfully released it for final distribution.

3 Oct 2009

New software to detect multiple sclerosis before brain damage occurs

Researchers of the Unit for Systems Biology of the University of Jaén, led by Francisco J. Esteban, are developing a software for clinical use to detect multiple sclerosis even before the typical brain damage of this neurodegenerative disease appear. In order to do so, this scientific multidisciplinary team is calculating the fractal dimension of the brain images registered on magnetic resonance imaging.

1 Oct 2009

Physician-assisted deaths do not cause significant grief among family members

Unlike other forms of suicide, physician assisted death does not cause substantial regret, or a sense of rejection among surviving family members. In addition, the prevalence and severity of depression and grief among family members whose loved ones received aid in dying is no different than family members whose loved ones did not pursue physician assisted suicide.

1 Oct 2009

EMD Serono submits NDA for Cladribine Tablets in the U.S.

EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).

1 Oct 2009

Tβ4 therapy in EAE mice improves neurological functional recovery

REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery.

30 Sep 2009

Multiple Sclerosis Society of Canada invites schools to participate in the 32nd MS Read-A-Thon

Multiple Sclerosis Society of Canada, Quebec Division is happy to announce the 32nd edition of the MS Read-A-Thon. This event invites students in elementary and secondary schools across the province to participate in an enjoyable activity that gives them a chance to develop their philanthropic qualities while stimulating their interest in reading.

29 Sep 2009

New scalable solutions for targeted re-sequencing studies from febit holding and Life Technologies

febit holding GmbH and Life Technologies Corporation today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted re-sequencing studies. In addition, febit will expand its Genomic Services Facility at Heidelberg by adding several Applied Biosystems SOLiD™ high-throughput sequencing systems and real-time PCR systems.

28 Sep 2009

La Jolla Institute scientist Hilde Cheroutre earns the 2009 NIH Director's Pioneer Award

A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award. The prestigious prize carries with it funding for total costs of up to $4.7 million over five years, and is designed to support the work of exceptionally creative scientists, whose novel proposals offer the potential to make extraordinary contributions to human health.

24 Sep 2009

Opexa Therapeutics' endeavor in the field of stem cell technology

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that it has achieved its first technology transfer milestone in connection with the company’s recently announced exclusive stem cell agreement with Novartis, one of the world’s largest healthcare companies. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa.

24 Sep 2009

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S. Food and Drug Administration (FDA) with the goal of expanding the biopharmaceutical company's U.S. immune globulin therapy portfolio by early 2010. The application was submitted for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), a blood-clotting disorder that can result in excessive bruising and bleeding.

24 Sep 2009

Drug registration process for Nutra Pharma's pain reliever begins

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

22 Sep 2009

"Help is Here Express" bus tour in South Carolina to provide prescription medicines for free

The "Help is Here Express" bus tour will be stopping in South Carolina throughout the week of September 21 - 25 at various cities in order to help uninsured and financially struggling South Carolinians access information on programs that provide prescription medicines for free or nearly free. With the state's unemployment rate now hitting 11.8 percent, the Partnership for Prescription Assistance (PPA) bus tour is raising awareness of patient assistance programs among state residents who face layoffs and loss of health care benefits.

22 Sep 2009

Researcher can anticipate immune response in Alzheimer's patients

A researcher who is working on a vaccine for Alzheimer's disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients. This continuing research at Ben-Gurion University of the Negev could one day lead to specific Alzheimer's vaccines that reduce plaque, neuronal damage and inflammation associated with the disease.

22 Sep 2009

FBC Acquisition commences tender offer to acquire all outstanding shares of Facet Biotech

Biogen Idec Inc. (NASDAQ:BIIB) announced today that FBC Acquisition Corp., its wholly owned subsidiary, has commenced a tender offer to acquire all of the outstanding shares of Facet Biotech Corporation (NASDAQ:FACT) for $14.50 per share in cash, in furtherance of its previously announced acquisition proposal. The tender offer is scheduled to expire at 12:00 midnight, ET, on October 19, 2009, unless extended or terminated.

22 Sep 2009

Sclerosis News and Research

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Multiple Sclerosis Association of America receives National Health Information Awards

Myocardial and neurological effects of Tβ4 presented

National experts to address epilepsy disorder

AMERIGROUP Foundation and ALS Association support the Grommet Island park project

Retinoic acid may provide relief for ulcerative colitis

Nutra Pharma manufactures first commercial batch of Cobroxin

New software to detect multiple sclerosis before brain damage occurs

Physician-assisted deaths do not cause significant grief among family members

EMD Serono submits NDA for Cladribine Tablets in the U.S.

Tβ4 therapy in EAE mice improves neurological functional recovery

Multiple Sclerosis Society of Canada invites schools to participate in the 32nd MS Read-A-Thon

New scalable solutions for targeted re-sequencing studies from febit holding and Life Technologies

La Jolla Institute scientist Hilde Cheroutre earns the 2009 NIH Director's Pioneer Award

Opexa Therapeutics' endeavor in the field of stem cell technology

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Drug registration process for Nutra Pharma's pain reliever begins

"Help is Here Express" bus tour in South Carolina to provide prescription medicines for free

Researcher can anticipate immune response in Alzheimer's patients

FBC Acquisition commences tender offer to acquire all outstanding shares of Facet Biotech

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News